Fiscal Performance Indicators - The narrow deficit ratio for 2026 is expected to decrease by approximately 0.04 percentage points compared to 2025, while the broad deficit ratio is projected to decline by about 0.67 percentage points[1] - If the 2026 fiscal revenue and expenditure are completed as budgeted, the year-on-year growth rate of narrow fiscal expenditure is expected to reach 4.6%, up from 3.7% in 2025, an increase of about 0.9 percentage points[2] - The year-on-year growth rate of broad fiscal expenditure is anticipated to be 5.3%, an increase of approximately 0.8 percentage points from 4.5% in 2025[2] Expected Growth in Physical Fiscal Expenditure - The expected year-on-year growth rate of physical broad fiscal expenditure is projected to be 4.8%, significantly higher than the 0.6% growth rate in 2025, marking an increase of about 4.2 percentage points[2] - The reasonable expected value for physical broad fiscal expenditure in 2026 is anticipated to achieve a year-on-year growth of around 2.6%, which is an increase of approximately 2 percentage points compared to the previous year[2] Sources of Growth in Fiscal Expenditure - The expected growth in physical broad fiscal expenditure is primarily driven by three factors: anticipated tax revenue growth, increased utilization of general public budget funds, and more allocations of "quasi-fiscal funds"[3] - It is estimated that physical broad fiscal expenditure will increase by approximately CNY 1.01 trillion in 2026 compared to 2025, with contributions of about CNY 474.6 billion from general public budget adjustments and CNY 465.5 billion from tax revenue growth[3] Investment Focus and Risks - The 2026 fiscal budget is expected to provide stronger support for physical work output compared to 2025, with a focus on expanding investment areas beyond traditional sectors[4] - Risks include potential underperformance of the fiscal budget execution, practical challenges in supporting equity investments, and inaccuracies in the expected surplus of government funds[4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a total revenue of 11.84 billion yuan in 2025, representing a year-on-year increase of 21.0%. The net profit attributable to shareholders was 2.87 billion yuan, up 32.6% year-on-year, with an EPS of 0.32 yuan [7] - The brokerage business saw significant growth, with revenue reaching 2.94 billion yuan, a 38.2% increase year-on-year, contributing 24.9% to total revenue. The market share in brokerage increased to 1.38%, up 8 basis points year-on-year [7] - The company is undergoing a transformation in wealth management, with new customer acquisition and active user numbers for its app reaching historical highs. The company is also ranked among the top in the industry for selling financial products [7] - The investment banking business showed signs of recovery, with revenue of 630 million yuan, a 10.0% decrease year-on-year, but the scale of equity underwriting increased significantly by 213.1% to 5.97 billion yuan [7] - The asset management business reached a record high in scale, with total assets under management at 127.2 billion yuan, a 25.9% increase year-on-year [7] - The self-operated investment income grew by 33.1% year-on-year, totaling 3.73 billion yuan [7] - The company expects continued growth in net profit for 2026 and 2027, estimating 3.83 billion yuan and 4.16 billion yuan respectively, with a projected net profit of 4.54 billion yuan for 2028 [7] Financial Projections - Total revenue projections for the company are as follows: 9.78 billion yuan in 2024, 11.84 billion yuan in 2025, 14.81 billion yuan in 2026, 15.59 billion yuan in 2027, and 16.76 billion yuan in 2028 [1] - The projected net profit attributable to shareholders is 2.16 billion yuan in 2024, 2.87 billion yuan in 2025, 3.83 billion yuan in 2026, 4.16 billion yuan in 2027, and 4.54 billion yuan in 2028 [1] - The estimated P/E ratios for the years 2026 to 2028 are 13.66, 12.57, and 11.53 respectively [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue of 2.918 billion yuan for 2025, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 354.39 million yuan, down 8.70% year-on-year [7] - The product structure has shown resilience, with the proportion of products priced above 300 yuan increasing by 6.01 percentage points to 25.53%, indicating a shift towards higher-end products [7] - The company is focusing on deepening its market presence in Northwest China while also targeting growth in Eastern and Northern markets [7] Financial Performance Summary - Revenue projections for the upcoming years are as follows: 3.011 billion yuan in 2026, 3.272 billion yuan in 2027, and 3.619 billion yuan in 2028, with expected growth rates of 3.17%, 8.66%, and 10.63% respectively [1] - The net profit attributable to shareholders is projected to be 362.50 million yuan in 2026, 413.82 million yuan in 2027, and 483.71 million yuan in 2028, with growth rates of 2.29%, 14.16%, and 16.89% respectively [1] - The company’s earnings per share (EPS) is expected to be 0.71 yuan in 2026, 0.82 yuan in 2027, and 0.95 yuan in 2028 [1] Market and Strategic Focus - The company aims to enhance its market share in the Northwest region while also focusing on the integration of new markets in Gansu and Qinghai, as well as in Shaanxi and Ningxia [7] - The introduction of a second employee stock ownership plan is expected to boost morale and align interests within the company [7] - The company is currently in a phase of adjustment within the liquor industry, with expectations for marginal improvements in the second half of 2026 [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has shown resilience in product structure upgrades and continues to deepen its market presence in the Northwest region [7] - In 2025, the company's revenue was 2.918 billion yuan, a year-on-year decrease of 3.40%, while the net profit attributable to the parent company was 354.39 million yuan, down 8.70% year-on-year [7] - The company is focusing on enhancing the proportion of high-end products, with revenue from products priced above 300 yuan increasing by 25.21% [7] - The company is expected to see a marginal improvement in the second half of 2026, with a long-term strategy focusing on national layout and deepening in the Northwest [7] Financial Forecasts - Total revenue forecast for 2024A is 3.021 billion yuan, with a projected growth of 18.59% [1] - The net profit attributable to the parent company for 2026E is expected to be 362.50 million yuan, reflecting a growth of 2.29% [1] - The earnings per share (EPS) for 2028E is projected to be 0.95 yuan, with a corresponding P/E ratio of 18.34 [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a total revenue of 5.38 billion yuan for 2025, representing a year-on-year growth of 24.76%. The net profit attributable to the parent company was 1.42 billion yuan, with a significant increase of 157.15% [7] - The company successfully opened 307 new stores, exceeding its annual target, bringing the total number of stores to 1,315 by the end of 2025. The same-store sales experienced a slight decline of 1.5% [7] - The company plans to open 350 new stores in 2026, with 140 already opened by March 20, 2026, and 14 more under construction [7] - The report indicates that the company is focusing on expanding in non-first-tier cities, with a notable increase in store numbers and revenue in these areas [7] - Profit margins in the second half of 2025 may fluctuate due to rising labor costs and the impact of new store openings in new cities [7] - The profit forecast for 2026 and 2027 has been adjusted to 1.92 billion yuan and 2.66 billion yuan, respectively, with a new forecast for 2028 at 3.79 billion yuan, indicating a growth of 35% and 39% [7] Financial Summary - Total revenue projections for the company are as follows: 5.38 billion yuan in 2025, 6.54 billion yuan in 2026, 7.74 billion yuan in 2027, and 9.11 billion yuan in 2028 [1][8] - The net profit attributable to the parent company is projected to be 1.92 billion yuan in 2026, 2.66 billion yuan in 2027, and 3.79 billion yuan in 2028 [1][8] - The earnings per share (EPS) are expected to be 1.08 yuan in 2026, 1.46 yuan in 2027, and 2.88 yuan in 2028 [1][8] - The price-to-earnings (P/E) ratio is projected to decrease from 50.93 in 2025 to 19.06 in 2028, indicating an improving valuation over time [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a total revenue of 3.881 billion yuan in 2025, representing a year-on-year increase of 17.8%. The net profit attributable to the parent company was 358.91 million yuan, up 11.0% year-on-year [7] - The gross profit margin was 21.2%, a decrease of 0.3 percentage points year-on-year, primarily due to revenue structure adjustments. The increase in net profit was lower than revenue growth, mainly due to a rise in marketing expenses and accounts receivable impairment [7] - The company expanded its property management services, with revenue reaching 2.225 billion yuan, a 24.9% increase year-on-year, driven by an increase in managed area [7] - Cash reserves are robust, with bank and cash on hand amounting to 3.432 billion yuan, a 17.7% increase year-on-year. The proposed final dividend is 0.15 HKD per share, with a special dividend of 0.05 HKD per share, resulting in a payout ratio of 69% [7] Financial Summary - Revenue projections for the company are as follows: 4.358 billion yuan in 2026, 4.836 billion yuan in 2027, and 5.304 billion yuan in 2028, with respective year-on-year growth rates of 12.3%, 10.9%, and 9.7% [1][8] - The net profit attributable to the parent company is expected to be 405.11 million yuan in 2026, 454.38 million yuan in 2027, and 509.38 million yuan in 2028, with year-on-year growth rates of 12.9%, 12.2%, and 12.1% respectively [1][8] - The company maintains a healthy financial structure with a debt-to-asset ratio of 54.96% and a price-to-earnings ratio (P/E) of 9.12 for 2025, projected to decrease to 6.42 by 2028 [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a total revenue of 11.84 billion yuan in 2025, representing a year-on-year increase of 21.0%. The net profit attributable to shareholders was 2.87 billion yuan, up 32.6% year-on-year, with an EPS of 0.32 yuan [7] - The brokerage business saw significant growth, with revenue increasing by 38.2% year-on-year to 2.94 billion yuan, accounting for 24.9% of total revenue. The market share in brokerage reached 1.38%, an increase of 8 basis points year-on-year [7] - The company is focusing on wealth management transformation, with new account market share and customer scale reaching historical highs. The company’s APP (Youlibao) monthly active users also hit record levels [7] - The investment banking business showed signs of recovery, with revenue of 630 million yuan, a year-on-year decrease of 10.0%. The company completed an equity underwriting scale of 5.97 billion yuan, up 213.1% year-on-year [7] - The asset management business reached a record high in scale, with a management size of 127.2 billion yuan, a year-on-year increase of 25.9% [7] - The self-operated investment income increased by 33.1% year-on-year to 3.73 billion yuan [7] - The company’s earnings forecast for 2026 and 2027 has been slightly adjusted, estimating net profits of 3.83 billion yuan and 4.16 billion yuan, respectively, with year-on-year growth of 33% and 9% [7] Financial Summary - Total revenue for 2025 is projected at 11.84 billion yuan, with a year-on-year growth of 21.0% [1] - The net profit attributable to shareholders is expected to be 2.87 billion yuan, reflecting a 32.6% increase year-on-year [1] - The estimated EPS for 2026 is 0.44 yuan, with a P/E ratio of 13.66 [1] - The company’s total assets are projected to reach 344.99 billion yuan by 2025 [15]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported a total revenue of 82.53 billion yuan in 2025, a decrease of 9.3% year-on-year, while the net profit attributable to shareholders was 8.11 billion yuan, an increase of 5.4% year-on-year [8] - The company has demonstrated cost control through technological innovation and enhanced logistics management, resulting in a decrease of 11.12% in comprehensive costs for cement and clinker products [8] - The company is actively expanding its industrial chain, with successful projects in both domestic and overseas markets, including the completion of the Yao Bai project in Xinjiang and the operation of the Phnom Penh Conch Cement project in Cambodia [8] - The company plans to maintain a capital expenditure of 118.20 billion yuan in 2026, while the cash dividend payout ratio for 2025 is 55.3%, an increase of 6.6 percentage points year-on-year [8] Financial Summary - The company expects net profit attributable to shareholders to reach 9.14 billion yuan in 2026, 10.12 billion yuan in 2027, and 11.08 billion yuan in 2028 [8] - The earnings per share (EPS) is projected to be 1.72 yuan in 2026, 1.91 yuan in 2027, and 2.09 yuan in 2028 [1] - The price-to-earnings (P/E) ratio is expected to decline from 15.05 in 2025 to 11.02 in 2028, indicating a potential increase in valuation as the market stabilizes [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a total revenue of 24.972 billion yuan for 2025, representing a year-on-year increase of 19.53%. The net profit attributable to shareholders was 12.35 billion yuan, up 18.91% year-on-year, with an EPS of 1.35 yuan [7] - The brokerage business saw significant growth, with revenues increasing by 43.8% year-on-year, contributing 35.6% to total revenue. The company also experienced a 40% increase in margin financing and securities lending balance [7] - The investment banking segment generated 1.03 billion yuan in revenue, a 20% increase year-on-year, with a total underwriting scale of 171.5 billion yuan [7] - Asset management revenue rose by 21.7% year-on-year, with the management scale of public funds increasing significantly [7] - The company is expected to see net profits of 13.6 billion yuan in 2026 and 14.6 billion yuan in 2027, reflecting growth rates of 10% and 7% respectively [7] Financial Summary - Total revenue forecast for 2024 is 20.891 billion yuan, increasing to 30.773 billion yuan by 2028, with a compound annual growth rate (CAGR) of approximately 4.14% [1] - The net profit attributable to shareholders is projected to grow from 10.386 billion yuan in 2024 to 15.494 billion yuan in 2028, with a CAGR of about 6% [1] - The company's P/E ratio is expected to decrease from 13.55 in 2024 to 8.59 in 2028, indicating an improving valuation over time [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2025 annual report shows performance in line with expectations, with a focus on accelerating innovation and international expansion [1] - Revenue for 2025 is projected at 12,020 million yuan, reflecting a year-on-year growth of 1.76%, while net profit attributable to shareholders is expected to be 2,023 million yuan, a decrease of 1.84% [1] - The company is enhancing its innovation pipeline with multiple new drug submissions and international market strategies, indicating a strong long-term growth potential [1] Financial Summary - Total revenue forecast for 2024A is 11,812 million yuan, with a projected increase to 15,449 million yuan by 2028E, showing a compound annual growth rate [1] - The net profit attributable to shareholders is expected to grow from 2,061 million yuan in 2024A to 2,777 million yuan in 2028E, indicating a positive trend in profitability [1] - The latest diluted EPS is projected to be 2.28 yuan for 2025A, with an expected increase to 3.13 yuan by 2028E [1] - The P/E ratio is forecasted to decrease from 14.95 in 2025A to 10.89 in 2028E, suggesting the stock may be undervalued [1] Segment Performance - The chemical preparation segment is expected to generate revenue of 62.2 billion yuan in 2025, with a gross margin of 81.1% [1] - The biopharmaceutical segment is projected to grow by 17.5%, while the traditional Chinese medicine segment is expected to see an 18.8% increase in revenue [1] - International revenue is anticipated to reach 19.3 billion yuan, reflecting a 12% growth, highlighting the company's successful international strategy [1] Innovation Pipeline - The company is accelerating its innovation pipeline with several key products, including IL-17A/F for psoriasis and other therapeutic areas, indicating a robust future product lineup [1] - New drug submissions are in progress, with several products expected to enter the market, enhancing the company's growth prospects [1]